OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now available Added reporting customized…
Month: August 2023
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care,…
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care,…
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage…
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage…
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
— Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and…
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
— Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and…
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
— VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within…
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
— VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within…
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
– Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced;…
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
– Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced;…
Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Arbor Biotechnologies®, a biotechnology company discovering and…
Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Arbor Biotechnologies®, a biotechnology company discovering and…
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191,…
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191,…
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate…
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate…
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in…